Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists

Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment

(2011) Joshua J. Neumiller   CLINICAL THERAPEUTICS

An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future

(2011) S. Madsbad et al.   DIABETES OBESITY & METABOLISM

The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension

(2011) H. Linnebjerg et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Treatment With Liraglutide-a Once-Daily GLP-1 Analog-Does Not Reduce the Bioavailability of Ethinyl Estradiol/Levonorgestrel Taken as an Oral Combination Contraceptive Drug

(2011) Lisbeth V. Jacobsen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

(2011) Goodarz Danaei et al.   LANCET

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

(2010) R. E. Ratner et al.   DIABETIC MEDICINE

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET